Table 1.

Targeted and nontargeted drugs used for in vivo drug screen

Target	Inhibitor	Dose, mg/kg	Schedule	Route	Solvent
CDK4/6	Palbociclib	50	QD	p.o.	Sodium lactate buffer (50 mM, pH 4.0)
Microtubule inhibitor	Abraxane	30	1x/week	i.p.	Saline
PI3K	Alpelisib	50	QD	i.p.	1% (wt/vol) Carboxymethylcellulose (CMC)+0.5% (wt/vol) Tween 80
RTK	Sunitinib	40	QD	p.o.	0.5% Carboxy-methylcellulose, ph3.5
JAK1/2	Ruxolitinib	60	QD	p.o.	0.1% Tween 80
HSP90	PU-H71	75	3x/week	p.o.	Phosphate buffer
EGFR	Erlotinib	25	QD	p.o.	0.5% methylcellulose
mTOR	Temsirolimus	10	QD	i.p.	4% ETOH+2% Tween 80+5% PEG 400
PI3K/mTOR	NVP-BEZ235	50	3x/week	p.o.	NMP/polyethylene glycol 300 (10/90, vol/vol)
IGF-R	BMS-754807	25	QD	p.o.	30% PEG400+0.5% Tween 80+5% Propylene glycol
Metabolism	Phenformin	100	QD	p.o.	Water
DNA	Gemcitabine	400	1x/week	i.p.	Saline
MEK1/2	Trametinib	2	QD	p.o.	0.5% HPMC+0.2%Tween 80
Src	Dasatinib	30	BID	p.o.	80 mM sodium citrate pH 3.1
DNA methyl transferase	5-Azacytidine (Decitabine)	3	QD	i.p.	Saline
BET bromodomain	(+)-JQ-1	50	QD	p.o.	10% 2-Hydroxypropyl-beta-cyclodextrin

BID, two times per day; i.p., intraperitoneal; p.o., per oral gavage; QD, every day.